Hepatitis Be Antibody

The Hepatitis Be Antibody test (anti-HBe, HBeAb) is used with complementary HBV serology and clinical data to define the phase of hepatitis B infection and estimate prognosis. It documents seroconversion from HBeAg positivity to anti-HBe positivity, aids in tracking the clinical course, and helps evaluate virologic response to antiviral therapy to inform management decisions.

Hepatitis B virus (HBV) is a DNA virus transmitted through blood and body fluids that can cause acute disease or progress to chronic infection with the potential for cirrhosis and hepatocellular carcinoma. Core serologic markers include HBsAg (envelope antigen), HBcAg, and the core-associated HBeAg; the presence of HBeAg signals active viral replication and heightened infectivity. Anti-HBe generally appears 8–16 weeks after infection as HBeAg clears and marks the end of the acute phase or a shift to a less replicative state. In patients with HBeAg-positive chronic hepatitis B, HBeAg-to–anti-HBe seroconversion correlates with virologic response to therapy. Reverse seroconversion (reappearance of HBeAg after prior anti-HBe) can occur with viral reactivation under immunosuppression. Anti-HBe may persist for up to five years and typically wanes before the development of anti-HBs and anti-HBc. Interpretation requires integration with other HBV markers and HBV DNA testing because precore/core promoter mutants may maintain infectivity despite anti-HBe positivity; in advanced cirrhosis, seroconversion does not necessarily translate into improved prognosis.